{
    "clinical_study": {
        "@rank": "111174", 
        "arm_group": {
            "arm_group_label": "Treatment (bryostatin 1, vincristine sulfate)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive bryostatin 1 IV over 24 hours followed immediately by vincristine IV. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients completing 6 courses of therapy may receive subsequent courses every 3 weeks and then every 4 weeks after 24 months of treatment. Patients may return to a 2- or 3-week treatment course at the discretion of the principal investigator.\nCohorts of 3 patients receive escalating doses of bryostatin 1 until the MTD is determined. The MTD is defined as the dose preceding that at which at least 1 of 3 patients experience dose-limiting toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase I trial is studying the side effects and best dose of bryostatin-1 when given\n      together with vincristine in treating patients with chronic lymphocytic leukemia,\n      non-Hodgkin's lymphoma, or multiple myeloma. Drugs used in chemotherapy use different ways\n      to stop cancer cells from dividing so they stop growing or die. Combining more than one drug\n      may kill more cancer cells"
        }, 
        "brief_title": "Bryostatin and Vincristine in B-Cell Malignancies", 
        "condition": [
            "Recurrent Adult Burkitt Lymphoma", 
            "Recurrent Adult Diffuse Large Cell Lymphoma", 
            "Recurrent Adult Diffuse Mixed Cell Lymphoma", 
            "Recurrent Adult Immunoblastic Large Cell Lymphoma", 
            "Recurrent Adult Lymphoblastic Lymphoma", 
            "Recurrent Grade 3 Follicular Lymphoma", 
            "Recurrent Mantle Cell Lymphoma", 
            "Refractory Chronic Lymphocytic Leukemia", 
            "Refractory Multiple Myeloma", 
            "Stage III Multiple Myeloma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Burkitt Lymphoma", 
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma", 
                "Lymphoma, Follicular", 
                "Lymphoma, Non-Hodgkin", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell", 
                "Lymphoma, Large B-Cell, Diffuse", 
                "Lymphoma, Large-Cell, Immunoblastic", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the maximum tolerated dose of bryostatin 1 as a 24 hour infusion and\n      vincristine when administered sequentially.\n\n      II. To determine the effect of this combination on programmed cell death (apoptosis).\n\n      III. To determine the immunomodulatory effect of bryostatin 1. IV. To observe patients for\n      clinical antitumor response after giving combination bryostatin 1 and vincristine.\n\n      OUTLINE: This is a dose-escalation study of bryostatin 1.\n\n      Patients receive bryostatin 1 IV over 24 hours followed immediately by vincristine IV.\n      Treatment repeats every 2 weeks in the absence of disease progression or unacceptable\n      toxicity. Patients completing 6 courses of therapy may receive subsequent courses every 3\n      weeks and then every 4 weeks after 24 months of treatment. Patients may return to a 2- or\n      3-week treatment course at the discretion of the principal investigator.\n\n      Cohorts of 3 patients receive escalating doses of bryostatin 1 until the maximum tolerated\n      dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 1\n      of 3 patients experience dose-limiting toxicity.\n\n      Patients are followed every 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with biopsy proven B-cell malignancies [e.g. chronic lymphocytic leukemia\n             (CLL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM)]; HIV-associated lymphomas\n             and acute leukemias are not eligible\n\n          -  Performance status: ECOG 0, 1, or 2\n\n          -  Life expectancy of at least 12 weeks\n\n          -  Patients with aggressive NHL will be enrolled after having failed all possible\n             therapy with curative intent\n\n          -  Patients with CLL must have failed an alkylating agent-containing regimen as well as\n             fludarabine chemotherapy\n\n          -  Patients with multiple myeloma must have received at least one prior chemotherapy\n             regimen and not be eligible for a dose intensification treatment approach\n\n          -  At least 4 weeks must have elapsed since prior large-field radiation therapy\n\n          -  Patients must have been off previous anti-cancer therapy for at least 3 weeks (6\n             weeks for BCNU and mitomycin C) and recovered from all treatment related toxicity\n\n          -  Prior vincristine therapy is allowed\n\n          -  Sexually active men and women must use an accepted and effective method of\n             contraception\n\n          -  In women of child-bearing age, a pregnancy test may be done at the discretion of the\n             investigator\n\n          -  Must have given written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients with brain metastasis, leptomeningeal involvement, primary CNS NHL, and\n             acute leukemia are ineligible\n\n          -  Patients with HIV infection are ineligible\n\n          -  WBC < 3000/ul\n\n          -  Granulocytes < 1500/ul\n\n          -  Platelets < 50,000/ul\n\n          -  Hemoglobin =< 8.5 g/dl\n\n          -  Bilirubin > 1.5 mg/dl\n\n          -  AST and ALT > 2 times normal\n\n          -  Creatinine > 2.0 mg/dl, and/or actual creatinine clearance < 40 ml/min/1.73 m^2; all\n             patients are required to have a 24 hr creatinine clearance\n\n          -  Clinical evidence of bleeding diathesis\n\n          -  ECOG Performance status 3 or 4\n\n          -  Patients who are pregnant or lactating; vincristine can cause fetal harm\n\n          -  Patients with clinically apparent neuropathy are ineligible (>= grade 2 neuropathy)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003166", 
            "org_study_id": "NCI-2012-03120", 
            "secondary_id": [
                "CWRU 3Y97", 
                "U01CA062502"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (bryostatin 1, vincristine sulfate)", 
                "description": "Given IV", 
                "intervention_name": "bryostatin 1", 
                "intervention_type": "Drug", 
                "other_name": [
                    "B705008K112", 
                    "BRYO", 
                    "Bryostatin"
                ]
            }, 
            {
                "arm_group_label": "Treatment (bryostatin 1, vincristine sulfate)", 
                "description": "Given IV", 
                "intervention_name": "vincristine sulfate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "leurocristine sulfate", 
                    "VCR", 
                    "Vincasar PFS"
                ]
            }, 
            {
                "arm_group_label": "Treatment (bryostatin 1, vincristine sulfate)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vincristine", 
                "Bryostatin 1"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44106"
                }, 
                "name": "Case Western Reserve University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Trial of Combination Bryostatin 1 (NSC 339555) and Vincristine in B-Cell Malignancies", 
        "overall_official": {
            "affiliation": "Case Western Reserve University", 
            "last_name": "Brenda Cooper", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2001", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "MTD", 
                "safety_issue": "Yes", 
                "time_frame": "2 weeks"
            }, 
            {
                "measure": "Response rates", 
                "safety_issue": "No", 
                "time_frame": "Up to 11 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003166"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "May 1998", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }, 
    "geocoordinates": {
        "Case Western Reserve University": "41.499 -81.695"
    }
}